Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: By either route, it's all the same

Journal of Clinical Oncology

Volumn 19, Issue 21, 2001, Pages 4093-4096

  Mayer, R J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE; UFT;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EDITORIAL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS;

EID: 0035503436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.21.4093     Document Type: Editorial

References (16)

1. Newer cytotoxic agents for advanced colon cancer
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
3. Toxicity of fluorouracil in patients with advanced colorectal cancer. Effect of administration schedule and prognostic factors
4. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
6. A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma
7. Oral fluoropyrimidines in the treatment of colorectal cancer
8. Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer
9. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
10. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
11. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C 85, an inactivator of dihydropyrimidine dehydrogenase
12. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
13. North American phase III study of oral eniluracil (EU) plus oral 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
14. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues
15. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
16. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study